Red shell- high risk normal tissue in stereotactic radiosurgery

  • Jun Yang
  • , Weihua Qi
  • , Lei Wang
  • , Qiuxia Lu
  • , Liangfu Han
  • , Brian Wang
  • , Weisi Yan

Research output: Contribution to journalReview articlepeer-review

Abstract

Due to the ablative nature of high prescription in Stereotactic Radiosurgery or stereotactic body radiation therapy (SRS/SBRT), the normal tissue surrounding the CTV receives the dose higher than tissue's dose constraint. A concept of Red Shell is proposed to define and quantify these tissue damaged in SBRT, using biological equivalent dose (BED) concept. The combination of biological factors and physics factors, including serial and parallel organ, dose gradient, dose distribution and fractionations, are further discussed to interpret the clinical meaning of Red Shell. This concept can also help planner to improve the optimization in planning process.

Original languageEnglish
Pages (from-to)273-277
Number of pages5
JournalPrecision Radiation Oncology
Volume7
Issue number4
DOIs
StatePublished - Dec 2023

Bibliographical note

Publisher Copyright:
© 2023 The Authors. Precision Radiation Oncology published by John Wiley & Sons Australia, Ltd on behalf of Shandong Cancer Hospital & Institute.

Funding

The authors are grateful to the pioneers of our field, Jack Fowler Ph.D. and Luther w Brady M.D. for their guidance in preparing and formulating this concept.

Keywords

  • Red Shell
  • biological equivalent dose
  • normal tissue
  • stereotactic radiosurgery
  • toxicity

ASJC Scopus subject areas

  • Oncology

Fingerprint

Dive into the research topics of 'Red shell- high risk normal tissue in stereotactic radiosurgery'. Together they form a unique fingerprint.

Cite this